Afatinib is a second‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is suggested as the primary treatment option for progressive, EGFR‐mutated NSCLC.3 Here, EGFR is linked to non-small cell lung carcinoma.